Coherus Oncology, Inc. (CHRS) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Coherus Oncology, Inc. is a commercial-stage innovative oncology company focused on its approved PD-1 inhibitor, LOQTORZI (toripalimab-tpzi), and a pipeline of mid-stage clinical candidates. The company recently completed a strategic shift by divesting its biosimilar businesses (UDENYCA, YUSIMRY, and CIMERLI), which are now reported as discontinued operations. The UDENYCA franchise was sold to Intas Pharmaceuticals in April 2025 for $483.4 million.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | YTD 9M 2025 | YTD 9M 2024 |
|---|---|---|---|---|
| Net Revenue (Continuing) | $11.6 million | $6.1 million | $29.4 million | $18.7 million |
| Net Loss (Continuing) | $(44.5) million | $(47.6) million | $(136.8) million | $(169.3) million |
| Net Income (Discontinued) | $9.0 million | $36.8 million | $342.4 million | $248.5 million |
| Total Net Income (Loss) | $(35.5) million | $(10.8) million | $205.7 million | $79.2 million |
| Cash & Equivalents | $103.4 million | $126.0 million | $103.4 million | $103.3 million |
| Marketable Securities | $88.3 million | $0 | $88.3 million | $0 |
| Total Liquidity | $191.7 million | $126.0 million | $191.7 million | $103.3 million |
| Debt Obligations | $37.0 million (Term Loan) | $265.0 million | $37.0 million | $265.0 million |
Note: Debt figures reflect the repayment of 2026 Convertible Notes and 2027 Term Loans in 2024/2025. Remaining debt is primarily the 2029 Term Loan.
Material Changes vs. Prior Period
- Revenue Growth: Continuing operations revenue increased 91% year-over-year in Q3 2025, driven by volume growth of LOQTORZI. Gross margin improved to 68% in Q3 2025 from 55% in Q3 2024.
- Discontinued Operations: The Q3 2025 net income from discontinued operations ($9.0 million) was significantly lower than Q3 2024 ($36.8 million) due to the completion of the UDENYCA sale in April 2025. However, the YTD 2025 figure includes a $338.7 million gain on the UDENYCA sale.
- Debt Reduction: The company repaid substantially all of its 2026 Convertible Notes and the remaining 2027 Term Loans using proceeds from the UDENYCA sale and a Revenue Purchase and Sale Agreement. Outstanding debt is now limited to the 2029 Term Loan ($38.7 million principal).
- Expense Management: Selling, General, and Administrative (SG&A) expenses decreased 11% in Q3 2025 compared to the prior year, primarily due to lower headcount and professional fees, partially offset by a $1.6 million impairment charge related to a terminated out-license.
Guidance, Outlook, and Risks
- Outlook: Management expects net revenue from continuing operations in 2025 to be higher than 2024 due to LOQTORZI growth. SG&A expenses are expected to be lower in 2025 due to reduced operating costs and headcount.
- Liquidity: The company believes its cash, cash equivalents, marketable securities ($191.7 million), and ATM Offering capacity ($64.9 million remaining) are sufficient to fund operations for at least the next 12 months.
- Recent Financing: On October 21, 2025 (post-period), the company completed a private placement raising $8.0 million for common stock and warrants.
- Key Risks:
- Internal Controls: A material weakness in internal control over financial reporting regarding inventory account reconciliations was identified in 2024. While remediation steps are underway, the specific control was decommissioned with the UDENYCA sale, preventing formal retesting in Q3 2025.
- Earnout Payments: The company is eligible for two potential earnout payments of $37.5 million each from the UDENYCA sale, contingent on future net sales thresholds.
- Regulatory & Competition: LOQTORZI faces competition from other PD-1 inhibitors. Regulatory approval for pipeline candidates (casdozokitug, CHS-114) is uncertain.
Investor Verification Checklist
- LOQTORZI Sales Trajectory: Verify the sustainability of the 91% revenue growth rate and gross margin expansion in the competitive PD-1 market.
- Discontinued Operations Accounting: Confirm the treatment of the $338.7 million gain on UDENYCA sale and the impact of the $8.7 million favorable settlement accrual release in Q3 2025.
- Internal Control Remediation: Monitor the status of the material weakness in inventory reconciliations and the effectiveness of new controls post-UDENYCA divestiture.
- Debt Covenants: Review compliance with the 2029 Term Loan covenants, specifically the requirement to maintain certain levels of cash and cash equivalents.
- Pipeline Milestones: Track progress of clinical trials for casdozokitug (HCC) and CHS-114 (HNSCC) and potential milestone payments to Junshi Biosciences.